Home
Live Updates
Data from Newrons study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS) | Region : comparemela.com
Data from Newron's study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS) | Region
MILAN--(BUSINESS WIRE)--Apr 8, 2024--
Related Keywords
Canada ,
Milan ,
Lombardia ,
Italy ,
Switzerland ,
Seika ,
Kyongsang Bukto ,
South Korea ,
India ,
United Kingdom ,
Sri Lanka ,
United States ,
United Arab Emirates ,
Bresso ,
Australia ,
Israel ,
Japan ,
Swiss ,
America ,
Stefan Weber ,
Paul Sagan ,
Anne Hennecke Caroline Bergmann ,
Valentin Handschin ,
Dusseldorf Stock Exchange ,
Newron Pharmaceuticals ,
Mc Services ,
European Union ,
Supernus Pharmaceuticals ,
Swiss Exchange ,
Schizophrenia International Research Society ,
Negative Syndrome Scale ,
Clinical Global Impression ,
Strauss Carpenter Level ,
Latin America ,
Meiji Seika ,
Ciara Martin ,
Natalie Garland Collins ,
Caroline Bergmann ,
Business Wire ,
comparemela.com © 2020. All Rights Reserved.